Cargando…

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

Background: Filgotinib (FIL) is a selective JAK1 inhibitor with an affinity 30-fold higher than JAK2, approved to treat moderate to severe active rheumatoid arthritis (RA), in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Methods: We co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benucci, Maurizio, Bardelli, Marco, Cazzato, Massimiliano, Laurino, Elenia, Bartoli, Francesca, Damiani, Arianna, Li Gobbi, Francesca, Panaccione, Anna, Di Cato, Luca, Niccoli, Laura, Frediani, Bruno, Mosca, Marta, Guiducci, Serena, Cantini, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532886/ https://www.ncbi.nlm.nih.gov/pubmed/37763071 http://dx.doi.org/10.3390/jpm13091303

Ejemplares similares

Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
por: Benucci, Maurizio, et al.
Publicado: (2020)

Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2020)

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
por: Niccoli, Laura, et al.
Publicado: (2018)

Correction to: Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2021)

Filgotinib: A Clinical Pharmacology Review
por: Namour, Florence, et al.
Publicado: (2022)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
por: Balsa, Alejandro, et al.
Publicado: (2023)

Performance Comparison of NB-Fi, Sigfox, and LoRaWAN
por: Levchenko, Polina, et al.
Publicado: (2022)

Compressed sensing in LiFi and WiFi networks
por: Benslama, Malek, et al.
Publicado: (2017)

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
por: Combe, Bernard, et al.
Publicado: (2022)

Evolution of Hybrid LiFi–WiFi Networks: A Survey
por: Besjedica, Toni, et al.
Publicado: (2023)

An Experimental Field Comparison of Wi-Fi HaLow and LoRa for the Smart Grid
por: Kane, Luke, et al.
Publicado: (2023)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study
por: Sebastiani, Marco, et al.
Publicado: (2023)

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
por: Bruni, Cosimo, et al.
Publicado: (2021)

The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective
por: Benucci, Maurizio, et al.
Publicado: (2022)

Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
por: Benucci, Maurizio, et al.
Publicado: (2018)

Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life
por: Benucci, Maurizio, et al.
Publicado: (2019)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy
por: Dal Buono, Arianna, et al.
Publicado: (2022)

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants
por: Anderson, Kacey, et al.
Publicado: (2021)

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
por: Benucci, Maurizio, et al.
Publicado: (2018)

Machine learning for DCO-OFDM based LiFi
por: Purnita, Krishna Saha, et al.
Publicado: (2021)

Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
por: Benucci, Maurizio, et al.
Publicado: (2022)

Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174
por: Benucci, Maurizio, et al.
Publicado: (2023)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies
por: Tani, Chiara, et al.
Publicado: (2021)

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
por: Benucci, Maurizio, et al.
Publicado: (2022)

Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Cantini, Fabrizio, et al.
Publicado: (2009)

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
por: Namour, Florence, et al.
Publicado: (2018)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial
por: Dotan, Iris, et al.
Publicado: (2023)

Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib
por: Reinisch, Walter, et al.
Publicado: (2022)

Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab
por: Benucci, Maurizio, et al.
Publicado: (2021)

Three-Phase Handover Management and Access Point Transition Scheme for Dynamic Load Balancing in Hybrid LiFi/WiFi Networks
por: Murad, Sallar Salam, et al.
Publicado: (2022)

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

Mid fi /
Publicado: (2011)

Fibrinogen (FI)
por: Fries, Dietmar, et al.
Publicado: (2015)

A Comprehensive Open-Source Simulation Framework for LiFi Communication
por: Ullah, Shakir, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o94sn6feqtnma95o2sut106dl3